Skip to main content
Aptabio Therapeutics Inc. logo

Aptabio Therapeutics Inc. — Investor Relations & Filings

Ticker · 293780 ISIN · KR7293780003 KO Manufacturing
Filings indexed 209 across all filing types
Latest filing 2024-08-28 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 293780

About Aptabio Therapeutics Inc.

https://aptabio.com/

Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.

Recent filings

Filing Released Lang Actions
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. This involves the issuance of new shares resulting from the conversion of debt into equity, which falls under capital changes. According to the provided definitions, announcements regarding new share issues or capital changes are classified as SHA.
2024-08-28 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for Aptabio Inc., covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial information, business operations, management discussions, and corporate governance details, which aligns with the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-14 Korean
타법인주식및출자증권취득결정
M&A Activity Classification · 100% confidence The document is a formal regulatory filing titled '타법인주식및출자증권취득결정' (Decision to acquire shares and equity securities of another corporation). It details the acquisition of shares in '주식회사 에프엠더블유' (FMW Co., Ltd.) by the company '압타바이오' (Aptabio). This type of disclosure is a standard corporate announcement regarding M&A activity or strategic investment, which falls under the 'TAR' (M&A Activity) category in the provided schema.
2024-07-23 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (기업설명회). It provides details such as the date, location, target audience, and purpose of the meeting. Since it is an announcement of an event rather than the presentation slides themselves, and it does not fit into other specific categories like earnings releases or financial reports, it is classified as a general regulatory filing/announcement.
2024-07-04 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for Aptabio Co., Ltd. covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial data, business operations, R&D activities, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-16 Korean
[기재정정]감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides a summary of financial data, audit opinions, and corrections to previously filed financial statements. While it contains financial data, it is a formal regulatory announcement of the audit report's submission and its subsequent correction, rather than the full annual report (10-K) itself. Therefore, it is classified as a Regulatory Filing (RNS). FY 2023
2024-04-30 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.